Skip to contentpdufa.bio
Home › Decisions › CYTK 2026-11-16

CYTK FDA decision: Nov 13, 2026 (announced Nov 16)

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET
✓ APPROVED

MYQORZO (Aficamten) was approved by the FDA for obstructive hypertrophic cardiomyopathy (MAPLE-HCM sNDA, aficamten vs metoprolol); the approval was announced on November 16, 2026.

Verified against: FDA action day November 13, 2026 (NDA 219083 S-002) · Announcement November 16, 2026 (Cytokinetics press release) · Goal date November 14, 2026 (CYTOKINETICS INC 8-K).

This page was first committed to pdufa.bio's public repository on Nov 17, 2026, 1:24 AM ET (public commit ce46f16). Dates on this page are the FDA's and the sponsor's; this line is ours.

Cytokinetics announced on November 16, 2026 that the FDA approved its sNDA adding Phase 3 MAPLE-HCM data (aficamten versus metoprolol) to the MYQORZO prescribing information; the indication is unchanged.

Run-up into the decision (T-120 → T+0)

announced 11/16/26$87.26$53.695/27/26announced 11/16/26$87.26$53.695/27/26
Daily close, T-120 (5/27/26) through T+0. Run-up high $87.26 on 6/29/26, low $53.69 on 11/6/26 (T-120 to T-1). Announced 11/16/26 (FDA action 11/13/26). Historical price action, not a forecast.

Key facts

FDA decision date2026-11-13
Announced2026-11-16
OutcomeApproved
Drug / candidateMYQORZO (aficamten) MAPLE-HCM sNDA
IndicationSymptomatic obstructive hypertrophic cardiomyopathy: label adds MAPLE-HCM data versus metoprolol
CompanyCytokinetics Inc
Market-cap tierMid
120-day run-up (T-120→T-1)-26.4%
Decision-day move-5.3%
Move measured on2026-11-16 close (the announcement day), against the 2026-11-13 close
Cohort decision-day move (history)2.3% median (n=230)

The PDUFA goal date was November 14, 2026 (a Saturday). The FDA's own record dates the action November 13, 2026, 1 day before the goal date; Cytokinetics announced it on November 16, 2026.

Run-up figures are the stock's own daily closing path over the 120 trading days before the decision, from our price history. Cohort move is the historical median absolute decision-day move for this market-cap tier. History, not a prediction.

Primary source: Cytokinetics press release, November 16, 2026

FDA record of the action: the FDA approved on November 13, 2026, per NDA 219083 S-002 (Drugs@FDA). The sponsor announced it on November 16, 2026. Action dates on pdufa.bio come from the FDA's own record, not the press release. Every FDA action we hold, by FDA date: FDA approval letters.

Specialist biotech funds holding CYTK, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
Avoro Capital Advisors4,900,000$323.0 millionfiled November 16, 2026
RTW Investments2,862,003$188.6 millionfiled November 16, 2026
Baker Bros. Advisors211,267$13.9 millionfiled November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

Was MYQORZO (aficamten) MAPLE-HCM sNDA approved by the FDA?

Yes. The FDA approved the application for MYQORZO (aficamten) MAPLE-HCM sNDA on November 13, 2026, per the FDA's own record. The company announced it on November 16, 2026. The primary source is linked on this page.

Which company is behind MYQORZO (aficamten) MAPLE-HCM sNDA?

MYQORZO (aficamten) MAPLE-HCM sNDA is a Cytokinetics Inc (CYTK) program. The FDA decision came on November 13, 2026; the company's own announcement is linked on this page.

How did CYTK stock react to the FDA decision?

CYTK moved -5.3%, measured as the 2026-11-16 close (the announcement day) against the 2026-11-13 close. It is one trading day's move, so it can include news other than the decision. Historical measurement, not a prediction, and not investment advice.